VK2809

VK2809
Clinical data
Other names	VK-2809; MB07811
Identifiers
	IUPAC name (2R,4S)-4-(3-Chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2λ5-dioxaphosphinan-2-one;
CAS Number	852948-13-1;
DrugBank	DB15137;
UNII	3Z11398FNQ;
CompTox Dashboard (EPA)	DTXSID501005783 ;
Chemical and physical data
Formula	C28H32ClO5P
Molar mass	514.98 g·mol−1

VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis^[1]^[2] and is also being investigated for glycogen storage disease type Ia.^[3]

References

^ "VK2809". Viking Therapeutics. Retrieved 15 September 2023.
^ Alkhouri, Naim (1 February 2020). "Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)". Expert Opinion on Investigational Drugs. 29 (2): 99–101. doi:10.1080/13543784.2020.1708899. ISSN 1354-3784.
^ Zhou, Jin; Waskowicz, Lauren R.; Lim, Andrea; Liao, Xiao-Hui; Lian, Brian; Masamune, Hiroko; Refetoff, Samuel; Tran, Brian; Koeberl, Dwight D.; Yen, Paul M. (1 August 2019). "A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia". Thyroid. 29 (8): 1158–1167. doi:10.1089/thy.2019.0007. ISSN 1050-7256. PMC 6707038. PMID 31337282.